$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa

$pcsa Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011976 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.271M	$1.149M	$5.658M
YoY Change	-48.73%	-56.25%	-35.44%
% of Gross Profit
Research & Development	$1.539M	$1.321M	$5.800M
YoY Change	-5.43%	-55.64%	-49.54%
% of Gross Profit
Depreciation & Amortization	$139.00	$220.00	$220.00
YoY Change		-99.89%
% of Gross Profit
Operating Expenses	$1.539M	$2.469M	$11.46M
YoY Change	-5.43%	-57.42%	-0.32%
Operating Profit	-$2.810M		-$11.46M
YoY Change	-31.57%		-58.38%
Interest Expense	$83.22K	$64.52K	$335.5K
YoY Change		16.19%	231.56%
% of Operating Profit
Other Income/Expense, Net	$83.22K
YoY Change	-0.29%
Pretax Income	-$2.726M	-$2.405M	-$11.12M
YoY Change	-32.21%	-81.52%	-59.45%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.700M	-$2.405M	-$11.12M
YoY Change	-32.87%	-81.52%	-59.45%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.11		-$8.48
Diluted Earnings Per Share	-$1.11	-$1.71	-$8.48
COMMON SHARES
Basic Shares Outstanding	2.856M shares	24.63M shares	1.312M shares
Diluted Shares Outstanding	2.467M shares		1.312M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.920M	$4.706M	$4.706M
YoY Change	-16.96%	-27.64%	-27.64%
Cash & Equivalents	$8.900M	$4.706M	$4.706M
Short-Term Investments
Other Short-Term Assets	$857.6K	$926.3K	$926.3K
YoY Change	-41.95%	-50.81%	-50.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$22.30K
Total Short-Term Assets	$9.800M	$5.633M	$5.633M
YoY Change	-19.8%	-32.84%	-32.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.415K	$148.6K	$148.6K
YoY Change		-34.7%	-34.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.540K	$5.540K	$5.540K
YoY Change	-97.4%	0.09%	0.0%
Total Long-Term Assets	$144.4K	$154.1K	$154.1K
YoY Change	-32.29%	-33.88%	-33.88%
TOTAL ASSETS
Total Short-Term Assets	$9.800M	$5.633M	$5.633M
Total Long-Term Assets	$144.4K	$154.1K	$154.1K
Total Assets	$9.945M	$5.787M	$5.787M
YoY Change	-20.01%	-32.87%	-32.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$455.4K	$311.6K	$311.6K
YoY Change	43.78%	-4.86%	-4.86%
Accrued Expenses	$465.6K	$229.9K	$229.9K
YoY Change	-70.42%	-42.96%	-52.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.800K
YoY Change
Total Short-Term Liabilities	$1.011M	$730.6K	$730.6K
YoY Change	-53.23%	-26.84%	-26.84%
LONG-TERM LIABILITIES
Long-Term Debt	$6.110K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$44.59K	$66.91K	$66.91K
YoY Change	-65.53%	-55.56%	-55.56%
Total Long-Term Liabilities	$50.70K	$66.91K	$66.91K
YoY Change	-60.81%	-55.56%	-55.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.011M	$730.6K	$730.6K
Total Long-Term Liabilities	$50.70K	$66.91K	$66.91K
Total Liabilities	$1.061M	$797.5K	$797.5K
YoY Change	-53.66%	-30.6%	-30.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$78.10M	-$75.40M
YoY Change	14.35%	17.45%
Common Stock	$87.28M	$80.66M
YoY Change	10.88%	12.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$300.0K	$300.0K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$8.883M	$4.989M	$4.989M
YoY Change
Total Liabilities & Shareholders Equity	$9.945M	$5.787M	$5.787M
YoY Change	-20.01%	-32.87%	-32.87%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.700M	-$2.405M	-$11.12M
YoY Change	-32.87%	-81.52%	-59.45%
Depreciation, Depletion And Amortization	$139.00	$220.00	$220.00
YoY Change		-99.89%
Cash From Operating Activities	-$2.000M	-$2.123M	-$8.063M
YoY Change	-5.4%	-14.98%	-16.01%
INVESTING ACTIVITIES
Capital Expenditures		$2.780K	$2.780K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$2.780K	-$2.780K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.321M
YoY Change			-1.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.263M	-31.28K	6.269M
YoY Change	-1.4%	-41.63%	-1712.15%
NET CHANGE
Cash From Operating Activities	-$2.000M	-2.123M	-8.063M
Cash From Investing Activities		-2.780K	-2.780K
Cash From Financing Activities	$6.263M	-31.28K	6.269M
Net Change In Cash	$4.214M	-2.157M	-1.797M
YoY Change	-0.56%	-15.43%	-82.02%
FREE CASH FLOW
Cash From Operating Activities	-$2.000M	-$2.123M	-$8.063M
Capital Expenditures		$2.780K	$2.780K
Free Cash Flow		-$2.126M	-$8.066M
YoY Change			-15.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001533743
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Depreciation Depreciation		usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023	dei	Local Phone Number LocalPhoneNumber	776-3133
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
CY2022	PCSA	Payments For Settlement Of Stock Awards PaymentsForSettlementOfStockAwards		usd
CY2023	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	PCSA	Stock Issued In Satisfaction Of Accrued Expense StockIssuedInSatisfactionOfAccruedExpense		usd
CY2023	PCSA	Stock Issued In Connection With Licensing Agreement Which Had Previously Been Recorded As Due To Licensor StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	PCSA	Operating Lease Liabilities OperatingLeaseLiabilities		usd
CY2023	PCSA	Non Cash Lease Liability Net NonCashLeaseLiabilityNet		usd
CY2022	PCSA	Non Cash Lease Liability Net NonCashLeaseLiabilityNet		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2023Q4	PCSA	Impairment Of Intangible Asset ImpairmentOfIntangibleAsset		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q4	PCSA	Deferred Tax Assets Startup Expenditures DeferredTaxAssetsStartupExpenditures		usd
CY2022Q4	PCSA	Deferred Tax Assets Startup Expenditures DeferredTaxAssetsStartupExpenditures		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets		usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39531
CY2023	dei	Entity Registrant Name EntityRegistrantName	Processa Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1539785
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7380 Coca Cola Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 106
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Hanover
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21076
CY2023	dei	City Area Code CityAreaCode	443
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	PCSA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	10200000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2855981	shares
CY2023	dei	Auditor Firm AuditorFirmId	6143
CY2023	dei	Auditor Name AuditorName	BD & Company, Inc
CY2023	dei	Auditor Location AuditorLocation	Owings Mills, MD
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4706197	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6503595	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	926300	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1883134	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5632497	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8386729	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2554	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	146057	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227587	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5535	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5535	usd
CY2023Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	151592	usd
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	233122	usd
CY2023Q4	us-gaap	Assets Assets	5786643	usd
CY2022Q4	us-gaap	Assets Assets	8619851	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	83649	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	78896	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	311617	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	327548	usd
CY2023Q4	PCSA	Due To Licensor DueToLicensor	189000	usd
CY2022Q4	PCSA	Due To Licensor DueToLicensor	189000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	39	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	51	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146274	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	403061	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	730579	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	998556	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	66905	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150554	usd
CY2023Q4	us-gaap	Liabilities Liabilities	797484	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1149110	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1291000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1286000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	806774	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	801774	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	129	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	80	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	80658111	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72018222	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	300000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64247561	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7470741	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8619851	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7268143	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	335541	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	101202	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11121520	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.48
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-34.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-34.05
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1311572	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1311572	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	805477	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	805477	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25485100	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	300000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8948713	usd
CY2022	PCSA	Shares Issued In Connection With Purchase Agreement Value SharesIssuedInConnectionWithPurchaseAgreementValue	450000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	400000	usd
CY2022	PCSA	Shares Withheld To Pay Income Tax On Stockbased Compensation SharesWithheldToPayIncomeTaxOnStockbasedCompensation	88843	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27424229	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7470741	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7470741	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1060339	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6352077	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1310875	usd
CY2023	PCSA	Adjustments To Additional Paid In Capital Settlement Of Stock Awards AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards	52746	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-30607	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4989159	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4989159	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11121520	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27424229	usd
CY2023	us-gaap	Depreciation Depreciation	222	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	81530	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	85518	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-189000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	115613	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	788495	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7268143	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1060339	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8828713	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1310875	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-956834	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-210549	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-78896	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-87937	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-15931	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	108643	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-12	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1721	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-70274	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-256787	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	243796	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8063346	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9605143	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2776	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2776	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6321470	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	88843	usd
CY2023	PCSA	Payments For Settlement Of Stock Awards PaymentsForSettlementOfStockAwards	52746	usd
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6268724	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-388843	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1797398	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9993986	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6503595	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16497581	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4706197	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6503595	usd
CY2022	PCSA	Stock Issued In Satisfaction Of Accrued Expense StockIssuedInSatisfactionOfAccruedExpense	120000	usd
CY2022	PCSA	Stock Issued In Connection With Licensing Agreement Which Had Previously Been Recorded As Due To Licensor StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor	400000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	450000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	238924	usd
CY2022	PCSA	Operating Lease Liabilities OperatingLeaseLiabilities	238924	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75400000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8100000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4700000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zky4ubR0Q093" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_znyFsFsCMCMl">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing our consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7300000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	296326	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	128943	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segments
CY2023	PCSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding And Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P2Y1M6D
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5799518	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11494230	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7400000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2371214	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8828713	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8943	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	341.34
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8943	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	341.34
CY2022	PCSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P2Y7M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1951	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	257.28
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6992	shares
CY2023Q4	PCSA	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice	364.72
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11121520	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27424229	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1311572	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1311572	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	805477	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	805477	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.48
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-34.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-34.05
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1311572	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1311572	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	805477	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	805477	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	296326	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	128943	shares
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023	us-gaap	Lease Cost LeaseCost	97000	usd
CY2022	us-gaap	Lease Cost LeaseCost	97000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	92389	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	70040	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	162429	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11875	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	150554	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	83649	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	66905	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11059429	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3791286	usd
CY2022Q4	PCSA	Impairment Of Intangible Asset ImpairmentOfIntangibleAsset	-7268143	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	788495	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	7300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	28600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	24000000.0	usd
CY2023	PCSA	Net Operating Loss Carryforward Expiry Date NetOperatingLossCarryforwardExpiryDate	2037
CY2023	PCSA	Net Operating Loss Carryforward Term NetOperatingLossCarryforwardTerm	P20Y
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Pursuant to Code Sec. 382 of the Internal Revenue Code (“the Code”), the utilization of our net operating loss carryforwards could be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec. 382 study and as such our net operating loss carryforwards may be subject to such limitation.
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0577	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0572	pure
CY2023	PCSA	Effective Income Tax Rate Reconciliation Income Tax Rate Permanent Differential EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential	-0.0025	pure
CY2022	PCSA	Effective Income Tax Rate Reconciliation Income Tax Rate Permanent Differential EffectiveIncomeTaxRateReconciliationIncomeTaxRatePermanentDifferential	-0.0055	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0141	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0093	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2793	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2710	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	6012941	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5048175	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1672436	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1431839	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3453799	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2590890	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	999	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	976	usd
CY2023Q4	PCSA	Deferred Tax Asset Acquired Inprocess Research And Development Tax Effected DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected	2500562	usd
CY2022Q4	PCSA	Deferred Tax Asset Acquired Inprocess Research And Development Tax Effected DeferredTaxAssetAcquiredInprocessResearchAndDevelopmentTaxEffected	2494829	usd
CY2023Q4	PCSA	Deferred Tax Assets Federal Orphan Drug Credits DeferredTaxAssetsFederalOrphanDrugCredits	1202955	usd
CY2022Q4	PCSA	Deferred Tax Assets Federal Orphan Drug Credits DeferredTaxAssetsFederalOrphanDrugCredits	1046539	usd
CY2023Q4	PCSA	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	2795379	usd
CY2022Q4	PCSA	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	1929462	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17639071	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14542710	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17639071	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14542710	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7400000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3100000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7400000	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-011976-index-headers.html	Edgar Link	pending
0001493152-24-011976-index.html	Edgar Link	pending
0001493152-24-011976.txt	Edgar Link	pending
0001493152-24-011976-xbrl.zip	Edgar Link	pending
audit_001.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-4.htm	Edgar Link	pending
ex4-4_001.jpg	Edgar Link	pending
ex4-4_002.jpg	Edgar Link	pending
ex4-4_003.jpg	Edgar Link	pending
ex4-4_004.jpg	Edgar Link	pending
ex4-4_005.jpg	Edgar Link	pending
ex4-4_006.jpg	Edgar Link	pending
ex4-4_007.jpg	Edgar Link	pending
ex4-4_008.jpg	Edgar Link	pending
ex4-4_009.jpg	Edgar Link	pending
ex4-4_010.jpg	Edgar Link	pending
ex4-4_011.jpg	Edgar Link	pending
ex4-4_012.jpg	Edgar Link	pending
ex4-4_013.jpg	Edgar Link	pending
ex4-4_014.jpg	Edgar Link	pending
ex4-4_015.jpg	Edgar Link	pending
ex4-4_016.jpg	Edgar Link	pending
ex4-4_017.jpg	Edgar Link	pending
ex4-4_018.jpg	Edgar Link	pending
ex4-4_019.jpg	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-kpipe_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
pcsa-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
pcsa-20231231_def.xml	Edgar Link	unprocessable
pcsa-20231231_lab.xml	Edgar Link	unprocessable
pcsa-20231231_pre.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pcsa-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa

2024 Q1 Form 10-K Financial Statement

#000149315224011976 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCSA Processa Pharmaceuticals, Inc. Stock $pcsa

2024 Q1 Form 10-K Financial Statement

#000149315224011976 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa